FDA greenlights first Ebola Virus treatment

by on

FDA greenlights first Ebola Virus treatment
tjordan_drupal
Oct 15, 2020

The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn) that, when combined, target glycoprotein on the Ebola virus’ surface to block its attachment and entry into the human body.

“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, M.D., MPH, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “The urgent need for advanced therapies to combat this infectious disease is clear, and today’s action is a significant step forward in that effort.”

Headline

FDA greenlights first Ebola Virus treatment
tjordan_drupal
Oct 15, 2020

The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn) that, when combined, target glycoprotein on the Ebola virus’ surface to block its attachment and entry into the human body.

“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, M.D., MPH, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “The urgent need for advanced therapies to combat this infectious disease is clear, and today’s action is a significant step forward in that effort.”

Ebola

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: